Apontis Pharma Deutschland GmbH & Co. KG

APONTIS Pharma has 10 launched single pills (fixed-dose combinations) in cardiovascular diseases novel to the German market and seeks partnerships to co-/develop 30+ more single pills in in/out-licensing business models strengthening our product portfolio. We depend on the partner for CDMO/CMO services including DDI, BE studies conduction, dossier preparation and submission on APONTIS behalf with ...